GlassScriptPhysician profile
Sean W Lee
NPI 1194765248
$20,881.22
in general payments reported to CMS, 2019-2025
53 companies · $5,573 in 2025
The $5,573 reported for 2025 was more than what 91% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,830 · 2020: $1,736 · 2021: $2,286 · 2022: $2,697 · 2023: $2,779 · 2024: $3,981 · 2025: $5,573.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,191.12 |
| Education | $140.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,137.15 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,056.71 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $2,814.31 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $1,304.95 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Gilead Sciences, INC. | $832.31 | 2019-2025 | |
| Qol Medical, LLC | $776.16 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $723.81 | 2019-2025 | |
| Madrigal Pharmaceuticals | $634.26 | 2024-2025 | Rezdiffra, Resmetirom |
| Phathom Pharmaceuticals, INC. | $474.15 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $472.55 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $412.21 | 2020-2025 | Ocaliva |
| Ardelyx, INC. | $411.63 | 2022-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $352.83 | 2019-2024 | Linzess |
| Merck Sharp & Dohme LLC | $307.92 | 2019-2024 | Dificid |
| Becton, Dickinson and Company | $246.97 | 2025 | Rotarexs 6 F X 135 Cm |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $226.07 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $175.08 | 2022-2025 | Dupixent |
| Vivus LLC | $170.44 | 2019-2024 | Qsymia |
| Ethicon US, LLC | $156.87 | 2019 | |
| Ucb, INC. | $138.06 | 2019-2020 | |
| Genzyme Corporation | $134.00 | 2022-2025 | |
| Daiichi Sankyo INC. | $133.23 | 2020-2025 | Injectafer |
| Celgene Corporation | $128.24 | 2021-2024 | Zeposia |
| Evoke Pharma, INC. | $125.49 | 2022-2024 | Gimoti |
| Sandoz INC. | $122.40 | 2024-2025 | Hyrimoz |
| Celltrion USA INC. | $120.41 | 2024-2025 | Vegzelma, Zymfentra |
| Romark Laboratories, Lc | $119.78 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $110.32 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $107.33 | 2024-2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $106.75 | 2025 | Iqirvo |
| Medtronic, INC. | $90.13 | 2022-2024 | Gi Genius |
| Redhill Biopharma INC. | $83.28 | 2020-2025 | Talicia |
| Nestle Healthcare Nutrition INC. | $76.00 | 2020-2023 | |
| Ferring Pharmaceuticals INC. | $70.93 | 2023-2024 | Rebyota |
| Organon LLC | $58.49 | 2023-2024 | Renflexis, Hadlima |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.73 | 2023 | Cyltezo |
| Orphalan INC | $45.29 | 2024-2025 | Cuvrior |
| Laborie Medical Technologies Corp. | $44.42 | 2023 | |
| Biocon Biologics INC | $39.85 | 2023-2025 | Yesintek, Hulio |
| Boston Scientific Corporation | $36.45 | 2019 | |
| Shionogi INC | $35.39 | 2019 | |
| Fresenius Kabi USA, LLC | $34.48 | 2023 | |
| Echosens North America, INC. | $28.85 | 2024 | Fibroscan |
| Olympus America INC. | $26.09 | 2023 | Endoclot Phs |
| Digestive Care, INC. | $25.94 | 2024 | Pertzye |
| Valinor Pharma, LLC | $23.09 | 2025 | Movantik |
| Concordia Pharmaceuticals INC. | $21.74 | 2019 | |
| Azurity Pharmaceuticals, INC. | $20.65 | 2025 | Suflave |
| Allergan, INC. | $14.71 | 2019 | |
| Alfasigma USA, INC. | $13.69 | 2020 | |
| Lucid Diagnostics INC. | $13.63 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.